OAB0503 Prevalence and incidence of tuberculosis infection and disease among household contacts exposed to rifampin-resistant/multidrug resistant tuberculosis (RR/MDR-TB)Oral Abstract SessionB10
OAB0504 Assessment of the tuberculosis clinical cascade among children living with HIV on antiretroviral therapy, 16 Sub-Saharan PEPFAR-supported programs, October 1, 2018 to March 31, 2019Oral Abstract SessionB10
OAB0505 Risk factors for hepatotoxicity in HIV-infected women receiving isoniazid preventive therapy in pregnancy and postpartumOral Abstract SessionB10
OAB0506 Validation of a laboratory-based reference test for TB-LAM and FLOW-TB, a novel point-of-care TB diagnostic assay, in a high-HIV-prevalence clinical cohort from KwaZulu-Natal, South AfricaOral Abstract SessionB10
OAB0507 TB contact investigations as an active HIV case finding strategy in Mozambique: Lessons for high TB and HIV syndemic countriesOral Abstract SessionB10
OAB0602 Weight gain and hyperglycemia during the dolutegravir transition in AfricaOral Abstract SessionB21
OAB0603 Changes in body mass index over time in persons with and without HIVOral Abstract SessionB22
OAB0604 Weight gain before and after switch from TDF to TAFOral Abstract SessionB22
OAB0605 Weight changes after switching to doravirine/lamivudine/TDF in the DRIVE-SHIFT trialOral Abstract SessionB22
OAB0606 Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO studyOral Abstract SessionB32
seek-warrow-warrow-eseek-e91 - 100 of 2297 items